This fifteenth annual European Group for Blood and Marrow Transplantation activity report lists the transplant activity in Europe in 2004 and documents the changes in indication over the past 15 years. In 2004, there were 22 216 first hematopoetic stem cells (HSCT), 7407 allogeneic (33%), 14 809 autologous (67%) and 4378 additional re-or multiple transplants reported from 592 centres in 38 European and five affiliated countries. Main indications were leukemias (7045 (32%; 78% allogeneic)); lymphomas (12 310 (55%; 94% autologous)); solid tumors (1759 (8%; 93% autologous)) and nonmalignant disorders (1015 (5%; 92% allogeneic)). In comparison, 145 teams from 20 countries performed 4234 HSCT (2137 allogeneic, 50%; 2097 autologous, 50%) in 1990. The overall increase was accompanied by major changes. Stem cell source changed from bone marrow to peripheral blood. More than one-third of allogeneic HSCT are now from unrelated donors. Reduced intensity conditioning is employed for one-third of allogeneic HSCT. Leukemias for allogeneic and lymphoproliferative disorders for autologous HSCT continue to increase. The decline in HSCT for chronic myeloid leukemia appears to level off for the first time since 1999. These data are informative for patient counselling and decision making for health care professionals.
Introduction
Transplantation of hematopoietic stem cells (HSCT) offers a unique opportunity for long-term disease control to many patients with severe malignant or hematopoietic stem cells malignant, acquired or congenital disorders of the hematopoietic system or with chemo-radiosensitive tumors. [1] [2] [3] HSC has seen rapid expansion over the last decade and the increasing demand for this high-cost procedure can present a challenge for health care systems in any country. Precise information on current use and trends is essential for patients, physicians and health care providers alike. 4, 5 The activity survey of the European Group for Blood and Marrow Transplantation (EBMT) was designed in 1990 to provide this information in a most efficient way and to disseminate it rapidly on an annual basis. 6 All EBMT members and affiliated teams, known to perform transplants, were requested to report their numbers of patients transplanted by indication, stem cell source and donor type on an annual basis. The initial survey sheet was slightly changed over the years, to respond to changes in indication and to collect additional generic information on the numbers of re-or multiple transplants, on the percentage of cord blood HSCT and on the percentage of transplants with reduced intensity conditioning (RIC HSCT). The EBMT survey was adopted by the General Assembly as a mandatory self-reporting system. It forms now an integral part of a comprehensive quality assurance program JACIE (Joint Accreditation Committee of the International Society for Cellular Therapy (ISCT) and the EBMT (http://www.EBMT.org/http://www.JACIE.org)). With a follow-up of 15 years since its introduction clear information becomes visible. Major changes have occurred concerning donor type, stem cell source, indications and technology. This is reflected in this 15th survey, which includes presentation of the 2004 data.
Patients and methods

Data collection and validation
All participating teams reported their data for 2004 by indication, stem cell source and donor type as listed in Table 1 . Data were validated by the reporting team, which received a computer printout of entered data, and by crosschecking with national registries. Onsite visits of selected teams were part of the quality control program.
Teams
For the 2004 report, 612 teams in 43 participating countries were contacted of which 592 reported their numbers. This corresponds to a 97% return rate of active teams and includes 481 of the 494 active EBMT member teams reporting to the survey. Twenty teams known by the investigators to have been performing HSCT in 2004 were also contacted, but chose not to reply or, for unknown reasons, failed to reply in spite of several efforts to reach them. No major transplant team in Europe is missing from this list. Contacted teams are listed in the Appendix A in alphabetical order according to country, city and EBMT centre code. We received information that in 2004 no blood or marrow transplants were performed in the following European countries: Albania, Andorra, Armenia, Georgia, Liechtenstein, Malta, Moldavia, Monaco, San Marino and The Vatican.
By EBMT tradition, some non-European countries; Algeria, Iran, Israel, Saudi Arabia and Tunisia are included in the survey and the analyses.
Definitions
The survey lists patients and transplants separately. For the determination of transplant rates, only first transplants were considered. Information on additional transplants, Transplant rates Transplant rates were defined as the number of HSCT per 10 million inhabitants. 5 They were computed by disease indication and donor type for each country, as previously defined. Transplant rates were assessed for all HSCT and separately for autologous, allogeneic and unrelated HSCT. They were also assessed for RIC allogeneic HSCT donor lymphocyte infusions (DLI) and cord blood HSCT. They were computed for all individual disease categories as given in Table 1 . Transplant rates refer to the number of transplants in a given country compared to its own population. The survey cannot make adjustments for patients who cross borders and receive their HSCT in a foreign country.
Population data were obtained from the US census office (http://www.census.gov).
Results
Participating teams
Of the 592 teams reporting HSCT in 2004, 342 (58%) did both allogeneic and autologous transplants; 224 (38%) restricted their activity to autologous, six teams (1%) to allogeneic transplants only. Twenty teams (3%) reported having performed no transplants in 2004. The development in numbers of transplant teams and transplants since 1973 when EBMT was founded is illustrated in Figure 1 . In 1990, at the introduction of the survey, 143 teams performed 4234 HSCT (2137 allogeneic (50%) and 2097 autologous (50%) HSCT For the 7407 allogeneic first transplants, HLA-identical siblings were used as donors for 4097 (55%) of the recipients, other family members for 432 (6%) of the recipients, a syngeneic twin for 40 (1%) of the recipients and an unrelated volunteer donor for 2838 (38%) of the recipients. Alternative donors were primarily used for patients with leukemias or nonmalignant disorders.
Stem cell source
Of the 14 809 autologous first transplants, 321 (2%) were bone marrow derived, 14 488 (98%) from peripheral blood stem cells or from combined bone marrow and peripheral blood stem cell transplants (Table 1) . Of the 7407 allogeneic first transplants, 31% were bone marrow and 69% were peripheral blood stem cell transplants. The proportion of peripheral blood as stem cell source varied depending on donor type. It was 68% for HLA-identical sibling donor transplants and 68% for unrelated donors. 82% for HSCT from other family members, 83% for twin donors.
A total 281 allogeneic HSCT were cord blood transplants in 2004. This corresponds to 3% of all allogeneic transplants.
Transplant rates
Transplant rates in 2004. There were marked differences in transplant rates between European countries and countries affiliated with EBMT as presented in Figure 2 . There was the previously reported difference between Eastern and Western European countries; these differences related to all transplants (Figure 2a) , to allogeneic HSCT ( Figure 2b ) and to autologous HSCT (Figure 2c ). Of interest to note is that countries with similar total transplant rates and higher transplant rates for allogeneic HSCT had lower transplant rates for autologous HSCT and vice versa.
Changes over time from 1990 to 2004
Stem cell source. Stem cell source was almost completely bone marrow in 1990, 6 it changed rapidly to peripheral blood for autologous HSCT, and more slowly and later for allogeneic HSCT (Figure 3 ). It is of interest to note that the proportion of peripheral blood as stem cell source was similar for the first time in 2004 in allogeneic HSCT from HLA-identical siblings and from unrelated donors.
Conditioning. Information on RIC HSCT is collected only since 1999. There were very few RIC HSCT before 1998 according to the EBMT megafile and a huge increase from 1999 to 2001 (Figure 4 ). In 2004, there were a total 2747 RIC HSCT. This corresponds to 31% of all allogeneic HSCT; a similar proportion over the past 3 years. There were marked differences in use of RIC HSCT amongst European countries with ranges from o1% (in 13 countries) to as much as 71% (in Austria) (Figure 2d ). and steady increases of about 50 HSCT per year for nonmalignant diseases in allogeneic and 50 HSCT per year for leukemias in autologous HSCT. There were major differences, when the individual disease categories are analysed as illustrated in Figure 6 . For acute myeloid leukemia (Figure 6a ) there was a steady increase in allogeneic HSCT, even more so for AML first CR in the past 3 years. Autologous HSCT in first CR did increase up to the year 2000, since then they plateaued. Autologous HSCT beyond first CR showed a slow decline. For acute lymphoblastic leukemia (Figure 6b ) there was an increase in allogeneic HSCT and a marked decline in autologous HSCT. Of interest to note, numbers of allogeneic HSCT in 1.CR increased at a higher rate than HSCT for ALL beyond first CR and were for the first time higher than HSCT beyond 1.CR. For chronic myeloid leukemia (Figure 6c ) there was a massive increase in HSCT up to the year 1999 (then the most frequent indication for an allogeneic HSCT) with a rapid decline. 4 This decline stopped in 2004 with similar numbers in 2003 (791) 8 and 2004 (802) . A high increase in allogeneic HSCT is observed for allogeneic HSCT for myelodysplastic-myeloproliferative disorders (Figure 6d ) with stable low numbers for autologous HSCT. A different pattern is observed for chronic lymphocytic leukemia with steadily increasing numbers for allogeneic, stable numbers since 1999 for autologous HSCT (Figure 6e ). Plasma cell disorders (Figure 6f) shows a rapid continuing increase in autologous HSCT. Numbers for allogeneic HSCT might be misleading in this specific disease. Only first transplants are captured by the survey. In myeloma, many teams use a tandemautologous allogeneic HSCT approach. This is not captured by the survey. In lymphoma, the main increase is seen in autologous HSCT for non-Hodgkins lymphoma (Figure 6g) . Transplants for solid tumors show changing patterns with increases for neuroblastoma and stable low numbers for glioma in autologous HSCT (Figure 6h ), increases in autologous HSCT for Ewings sarcoma (Figure 6i ) and decreasing numbers for soft tissue tumors. Most marked is the previously well-described increase and decrease in autologous HSCT for breast cancer (Figure 6j ). Numbers of allogeneic HSCT for solid tumors remained low throughout the whole observation period (Table 1) . Allogeneic HSCT did increase for the bone marrow failure syndromes, congenital disorders and for hemoglobinopathies (Figure 6k ). 
Changes in indication.
Discussion
The present data document that HSCT is a well-established procedure in Europe in 2004. Autologous and allogeneic stem cells from different sources were used for a broad variety of disorders. Peripheral blood was the main source of stem cells with the few exceptions of allogeneic HSCT for nonmalignant disorders. Autologous HSCT was the preferred choice for those disease categories, where primary focus lies on support for dose intensification of chemoradiotherapy, that is in specified solid tumors and lymphomas. Allogeneic HSCT was the preferred choice where focus was on replacing a defective hemopoiesis as in congenital disorders or bone marrow failure syndromes or in malignant diseases involving hemopoiesis and in which a graft-versus-tumor effect is most desired, for example, leukemias. 9, 10 As such, data reflect current status. More informative are data, if they are put in context over time. It is illustrative to note the differences in trends amongst the leukemias with a most marked increase in allogeneic HSCT for early acute leukemias, myelodysplastic and myeloproliferative syndromes and chronic lymphocytic leukemia. In chronic myeloid leukemia, the imatinibinduced fall in HSCT has stabilised and numbers remained similar between 2003 and 2004, with still higher numbers for HSCT in first chronic phase compared to later stages of the disease. 5, 11, 12 According to the structure of the survey, no information is yet available on the proportion of these patients with imatinib pre-treatment or imatinib failure. Numbers of autologous HSCT increased mainly for lymphoproliferative disorders. This is clearly explained by the several prospective randomised studies which showed an advantage of autologous HSCT compared to conventional therapy. [13] [14] [15] There are a few specific comments. Increase in AML in first CR is most marked during the past years. This is most likely the consequence of increased use of RIC HSCT in elderly patients. It cannot be proven by the survey. Unexplained remains the higher increase of allogeneic HSCT for ALL in first CR compared to later stages. Unexplained remains the pattern of transplant evolution in CLL. In addition, numbers of allogeneic HSCT, specifically for multiple myeloma or Hodgkin's disease might be misleading. Owing to the nature of the survey, the information on allogeneic HSCT after a preceeding autologous HSCT cannot be captured. [16] [17] [18] The fact, that numbers of double transplants have declined for autologous but increased for allogeneic HSCT support the assumption, that allogeneic HSCT have increased for myeloma and lymphoma. The survey for 2005 will be adapted and will yield such information.
The survey gives very limited information on technological aspects of HSCT procedure. Still, it documents the change in stem cell source where now peripheral blood is the preferred source of choice for all situations, with the exception of bone marrow failure syndromes. 8, 19, 20 It is interesting that the proportion reaches similar values for The survey gives some generic information on the use of RIC HSCT. 9, 10 About one-third of all allogeneic HSCT are RIC HSCT, the trend appears now stable with a similar proportion over the past 3 years. Still and important to note, there was a marked discrepancy in use between the different European countries. This difference reflects the divergent opinions amongst the transplant physicians about the value of this approach in general. It reflects probably best the need for prospective trials which should evaluate the role of RIC HSCT compared to standard conditioning or compared to alternative treatment.
As usual, the survey gives no information on outcome. These data will be reported later, when this information becomes available with sufficient follow-up. As it stands, the survey presents current status and trends. It forms the basis for decision making for individual patients, physicians, transplant teams and health care providers.
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